| 1 |
Kamran S, Anwar R, Noor A, Ullah MI, Bagalagel AA, Aldurdunji MM, Ishtiaq S. Metabolic Profiling and Investigation of the Modulatory Effect of Fagonia cretica L. Aerial Parts on Hepatic CYP3A4 and UGT2B7 Enzymes in Streptozotocin-Induced Diabetic Model. Antioxidants (Basel) 2023;12. [PMID: 36670981 DOI: 10.3390/antiox12010119] [Reference Citation Analysis]
|
| 2 |
Xiong S, Li X, Chu H, Deng Z, Sun L, Liu J, Mu Y, Yao Q. Comparative pharmacokinetics of four major compounds after oral administration of Mori Cortex total flavonoid extract in normal and diabetic rats. Front Pharmacol 2023;14:1148332. [PMID: 36937873 DOI: 10.3389/fphar.2023.1148332] [Reference Citation Analysis]
|
| 3 |
Mittal G, Jakhar P, Patel A, Bhagwat DP. Pharmacokinetic assessment of cefpodoxime proxetil in diabetic rats. J Diabetes Metab Disord 2022. [DOI: 10.1007/s40200-022-01156-3] [Reference Citation Analysis]
|
| 4 |
Park CH, Song MJ, Jung BW, Park JH, Jung YS. Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication. J Pers Med 2022;12. [PMID: 36422094 DOI: 10.3390/jpm12111918] [Reference Citation Analysis]
|
| 5 |
Gill AS, Gorski M, Strage KE, Dunn JT, Jerabek M, Hoffman KM. Oral Versus Intravenous Antibiotics for Residual Osteomyelitis After Amputation in the Diabetic Foot. J Foot Ankle Surg 2022;61:735-8. [PMID: 34953668 DOI: 10.1053/j.jfas.2021.11.006] [Reference Citation Analysis]
|
| 6 |
Azab ET, Thabit AK, Mckee S, Al-qiraiqiri A. Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens? Gut Pathog 2022;14. [DOI: 10.1186/s13099-022-00502-3] [Reference Citation Analysis]
|
| 7 |
Song Y, Wang X, Chen C, Wei T, Lang K, Yang D, Song Y. Weaker Response to XueBiJing Treatment in Severe Community-Acquired Pneumonia Patients With Higher Body Mass Index or Hyperglycemia: A Post Hoc Analysis of a Randomized Controlled Trial. Front Pharmacol 2022;13:755536. [DOI: 10.3389/fphar.2022.755536] [Reference Citation Analysis]
|
| 8 |
El-sheikh SM, Metwally AS, Galal AA. Impact of diabetes mellitus on rifampicin's plasma concentration and bioavailability in patients with tuberculosis: A systematic review and meta-analysis study. Therapies 2022. [DOI: 10.1016/j.therap.2022.05.005] [Reference Citation Analysis]
|
| 9 |
Nakamura E, Sofue T, Kunisho Y, Onishi K, Yamaguchi K, Ibuki E, Taoka R, Ueda N, Sugimoto M, Minamino T. Transplant Prognosis in Kidney Transplant Recipients with Diabetes under Mycophenolic Acid-Focused Therapeutic Drug Monitoring. J Pers Med 2021;11:1224. [PMID: 34834579 DOI: 10.3390/jpm11111224] [Reference Citation Analysis]
|
| 10 |
Hakami T, Mahmoud MI, de Juan E, Cooney M. Pharmacokinetics of genistein distribution in blood and retinas of diabetic and non-diabetic rats. Drug Metab Pharmacokinet 2021;39:100404. [PMID: 34171772 DOI: 10.1016/j.dmpk.2021.100404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Hu Y, Zheng X, Davies Forsman L, Ning Z, Chen C, Gao Y, Zhang Z, Lu W, Werngren J, Bruchfeld J, Hoffner S, Xu B. Emergence of additional drug resistance during treatment of multidrug-resistant tuberculosis in China: a prospective cohort study. Clin Microbiol Infect 2021:S1198-743X(21)00169-5. [PMID: 33895338 DOI: 10.1016/j.cmi.2021.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 12 |
Mann SC, Morrow M, Coyle RP, Coleman SS, Saderup A, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL, Castillo-Mancilla JR. Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus. J Acquir Immune Defic Syndr 2020;85:483-8. [PMID: 33136749 DOI: 10.1097/QAI.0000000000002460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Song X, Cai C, Jin Q, Chen X, Yu C. The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis. Helicobacter 2021;26:e12781. [PMID: 33465265 DOI: 10.1111/hel.12781] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 14 |
Gautam RK, Mishra R, Sharma K, Sharma M. Cellular and Molecular Mechanisms of Repurposed Antidiabetic Drug as an Adjunctive Treatment for Tuberculosis. Targeting Cellular Signalling Pathways in Lung Diseases 2021. [DOI: 10.1007/978-981-33-6827-9_15] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 15 |
Zheng Z, Pan X, Xu J, Wu Z, Zhang Y, Wang K. Advances in tracking of polysaccharides in vivo: Labeling strategies, potential factors and applications based on pharmacokinetic characteristics. International Journal of Biological Macromolecules 2020;163:1403-20. [DOI: 10.1016/j.ijbiomac.2020.07.210] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 16 |
Mtabho CM, Semvua HH, van den Boogaard J, Irongo CF, Boeree MJ, Colbers A, Burger DM, van Crevel R, van der Ven AJAM, Kibiki GS, Tostmann A, Aarnoutse RE. Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients. J Antimicrob Chemother 2019;74:3537-45. [PMID: 31651031 DOI: 10.1093/jac/dkz368] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Smith RG. Clinical Coping with Prescribing Opioids within the Context of Obesity and Diabetes Mellitus. JOD 2019. [DOI: 10.33805/2638-812x.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 18 |
Smith RG. Clinical Coping with Prescribing Opioids within the Context of Obesity and Diabetes Mellitus. JOH 2019. [DOI: 10.33805/2638-812x.117] [Reference Citation Analysis]
|
| 19 |
Yao CC, Kuo CM, Hsu CN, Yang SC, Wu CK, Tai WC, Liang CM, Wu KL, Huang CF, Bi KW, Lee CH, Chuah SK. First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus. Infect Drug Resist 2019;12:1425-31. [PMID: 31239721 DOI: 10.2147/IDR.S194584] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 20 |
Mashayekhi-Sardoo H, Mohammadpour AH, Nomani H, Sahebkar A. The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs. J Cell Physiol 2019;234:19339-51. [PMID: 31017666 DOI: 10.1002/jcp.28644] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 21 |
Dvořáčková E, Novotný M. Effect of diabetic nephropathy on drug pharmacokinetics. Prakticke lekarenstvi 2018;14:175-178. [DOI: 10.36290/lek.2018.033] [Reference Citation Analysis]
|
| 22 |
Barnes RC, Kim H, Fang C, Bennett W, Nemec M, Sirven MA, Suchodolski JS, Deutz N, Britton RA, Mertens-Talcott SU, Talcott ST. Body Mass Index as a Determinant of Systemic Exposure to Gallotannin Metabolites during 6-Week Consumption of Mango (Mangifera indica L.) and Modulation of Intestinal Microbiota in Lean and Obese Individuals. Mol Nutr Food Res 2019;63:e1800512. [PMID: 30427574 DOI: 10.1002/mnfr.201800512] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Tatara AM, Kontoyiannis DP, Mikos AG. Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions. Adv Drug Deliv Rev 2018;129:319-29. [PMID: 29221962 DOI: 10.1016/j.addr.2017.12.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 24 |
Akhlaghi F, Matson KL, Mohammadpour AH, Kelly M, Karimani A. Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus. Clin Pharmacokinet 2017;56:561-71. [PMID: 27832452 DOI: 10.1007/s40262-016-0472-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 25 |
Okour M, Jacobson PA, Ahmed MA, Israni AK, Brundage RC. Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure. J Clin Pharmacol 2018;58:628-39. [PMID: 29329489 DOI: 10.1002/jcph.1064] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 26 |
Lambooy SPH, Bidadkosh A, Nakladal D, van Buiten A, Girgis RAT, van der Graaf AC, Wiedenmann TJ, Koster RA, Vogelaar P, Buikema H, Henning RH, Deelman LE. The Novel Compound Sul-121 Preserves Endothelial Function and Inhibits Progression of Kidney Damage in Type 2 Diabetes Mellitus in Mice. Sci Rep 2017;7:11165. [PMID: 28894214 DOI: 10.1038/s41598-017-11582-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 27 |
Okada A, Ushigome H, Kanamori M, Morikochi A, Kasai H, Kosaka T, Kokuhu T, Nishimura A, Shibata N, Fukushima K, Yoshimura N, Sugioka N. Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center. Eur J Clin Pharmacol 2017;73:1111-9. [PMID: 28620753 DOI: 10.1007/s00228-017-2279-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 28 |
Bruch R, Chatelle C, Kling A, Rebmann B, Wirth S, Schumann S, Weber W, Dincer C, Urban G. Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy. Sci Rep 2017;7:3127. [PMID: 28600499 DOI: 10.1038/s41598-017-03338-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 29 |
Kim SE, Park MI, Park SJ, Moon W, Kim JH, Jung K, Kim HK, Lee YD. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J Gastroenterol 2017; 23(6): 1059-1066 [PMID: 28246480 DOI: 10.3748/wjg.v23.i6.1059] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 30 |
Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis 2017;17:125. [PMID: 28166721 DOI: 10.1186/s12879-017-2226-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 31 |
Yoo J, Yu YJ, Cho G, Oh H, Oh SH, Kim TH, Oh JH. Helicobacter pylori Eradication Rate in Patients with Diabetes. Korean J Helicobacter Up Gastrointest Res 2017;17:83. [DOI: 10.7704/kjhugr.2017.17.2.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 32 |
Redan BW, Buhman KK, Novotny JA, Ferruzzi MG. Altered Transport and Metabolism of Phenolic Compounds in Obesity and Diabetes: Implications for Functional Food Development and Assessment. Adv Nutr 2016;7:1090-104. [PMID: 28140326 DOI: 10.3945/an.116.013029] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 33 |
Siddiqui AN, Khayyam KU, Sharma M. Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study. Biomed Res Int 2016;2016:7273935. [PMID: 27642601 DOI: 10.1155/2016/7273935] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 34 |
Darvhekar V, Tripathi AS, Jyotishi SG, Mazumder PM, Shelke PG. Influence of Musa sapientum L. on pharmacokinetic of metformin in diabetic gastroparesis. Chin J Integr Med 2016;22:783-8. [DOI: 10.1007/s11655-016-2520-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 35 |
Tsai D, Jamal JA, Davis JS, Lipman J, Roberts JA. Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet 2015;54:243-60. [PMID: 25385446 DOI: 10.1007/s40262-014-0209-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 36 |
Anguizola J, Debolt E, Suresh D, Hage DS. Chromatographic analysis of the effects of fatty acids and glycation on binding by probes for Sudlow sites I and II to human serum albumin. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1021:175-81. [PMID: 26468085 DOI: 10.1016/j.jchromb.2015.09.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 37 |
Medellín-Garibay SE, Cortez-Espinosa N, Milán-Segovia RC, Magaña-Aquino M, Vargas-Morales JM, González-Amaro R, Portales-Pérez DP, Romano-Moreno S. Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters. Antimicrob Agents Chemother 2015;59:7707-14. [PMID: 26438503 DOI: 10.1128/AAC.01067-15] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 38 |
Kim S, Hwang J. Preoperative glycosylated haemoglobin as a predictor of postoperative analgesic requirements in diabetic patients: A prospective observational study. European Journal of Anaesthesiology 2015;32:705-11. [DOI: 10.1097/eja.0000000000000282] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 39 |
Alkabab YM, Al-Abdely HM, Heysell SK. Diabetes-related tuberculosis in the Middle East: an urgent need for regional research. Int J Infect Dis 2015;40:64-70. [PMID: 26409203 DOI: 10.1016/j.ijid.2015.09.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 40 |
Sapmaz F, Kalkan IH, Suslu I, Demirci H, Atasoy P, Guliter S. Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus. J Dig Dis 2015;16:531-6. [PMID: 26147605 DOI: 10.1111/1751-2980.12272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 41 |
Wilby KJ, Ensom MH, Marra F. Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults. Clin Pharmacokinet 2014;53:873-90. [PMID: 25172553 DOI: 10.1007/s40262-014-0170-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 42 |
Wang JY, Lee MC, Shu CC, Lee CH, Lee LN, Chao KM, Chang FY. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? Chest 2015;147:520-8. [PMID: 25255302 DOI: 10.1378/chest.14-0918] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 43 |
Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H. High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2014;106:81-87. [PMID: 25110103 DOI: 10.1016/j.diabres.2014.07.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 44 |
Tripathi AS, Mazumder PM, Chandewar AV. Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy. J Diabetes Metab Disord 2014;13:8. [PMID: 24398037 DOI: 10.1186/2251-6581-13-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 45 |
Baghaei P, Marjani M, Javanmard P, Tabarsi P, Masjedi MR. Diabetes mellitus and tuberculosis facts and controversies. J Diabetes Metab Disord 2013;12:58. [PMID: 24360398 DOI: 10.1186/2251-6581-12-58] [Cited by in Crossref: 54] [Cited by in F6Publishing: 68] [Article Influence: 5.4] [Reference Citation Analysis]
|
| 46 |
Heysell SK, Moore JL, Staley D, Dodge D, Houpt ER. Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA. Tuberc Res Treat 2013;2013:129723. [PMID: 24349775 DOI: 10.1155/2013/129723] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 47 |
Lavasani H, Sheikholeslami B, Ardakani YH, Abdollahi M, Hakemi L, Rouini MR. Study of the pharmacokinetic changes of Tramadol in diabetic rats. Daru 2013;21:17. [PMID: 23497674 DOI: 10.1186/2008-2231-21-17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 48 |
Dostalek M, Akhlaghi F, Puzanovova M. Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs. Clin Pharmacokinet 2012;51:481-99. [DOI: 10.1007/bf03261926] [Cited by in Crossref: 80] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 49 |
Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, Shin S, Murray M, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis 2013;56:770-6. [PMID: 23223591 DOI: 10.1093/cid/cis1008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 50 |
Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet 2012;51:481-99. [PMID: 22668340 DOI: 10.2165/11631900-000000000-00000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 37] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 51 |
Lee JH, Lee A, Oh J, Lee Y. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats: COMPARATIVE PHARMACOKINETICS OF TAXANES IN DIABETIC RATS. Biopharm Drug Dispos 2012;33:474-86. [DOI: 10.1002/bdd.1814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 52 |
Cao Y, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats. Biopharm Drug Dispos 2012;33:285-91. [PMID: 22782506 DOI: 10.1002/bdd.1797] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 53 |
Valle A, Catalán V, Rodríguez A, Rotellar F, Valentí V, Silva C, Salvador J, Frühbeck G, Gómez-Ambrosi J, Roca P, Oliver J. Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects. Liver Int 2012;32:951-61. [PMID: 22340678 DOI: 10.1111/j.1478-3231.2012.02765.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 54 |
Anger GJ, Cressman AM, Piquette-Miller M. Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes. PLoS One 2012;7:e35027. [PMID: 22558111 DOI: 10.1371/journal.pone.0035027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 55 |
Requena-Méndez A, Davies G, Ardrey A, Jave O, López-Romero SL, Ward SA, Moore DA. Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV. Antimicrob Agents Chemother 2012;56:2357-63. [PMID: 22330931 DOI: 10.1128/AAC.06059-11] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 56 |
Anger GJ, Piquette-miller M. Mechanisms of Reduced Maternal and Fetal Lopinavir Exposure in a Rat Model of Gestational Diabetes. Drug Metab Dispos 2011;39:1850-9. [DOI: 10.1124/dmd.111.040626] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Ponte CM, Gurgel MH, Ponte GA, Ramos AV, Montenegro Júnior RM. [Metabolic disorders in emerging and neglected infectious diseases]. Arq Bras Endocrinol Metabol 2010;54:785-92. [PMID: 21340170 DOI: 10.1590/s0004-27302010000900003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 58 |
Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010;16:1546-53. [PMID: 20875279 DOI: 10.3201/eid1610.100374] [Cited by in Crossref: 102] [Cited by in F6Publishing: 111] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 59 |
Park JM, Lake KD, Cibrik DM. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. Ther Drug Monit 2008;30:591-6. [PMID: 18708992 DOI: 10.1097/FTD.0b013e3181858169] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 60 |
Basiaga SB, Hage DS. Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:3193-7. [PMID: 20974553 DOI: 10.1016/j.jchromb.2010.09.033] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 61 |
Tedesco-silva H, Felipe CR, Park SI, Pinheiro-machado PG, Garcia R, Slade A, Schmouder R, Medina-pestana JO. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients: Variability of MPA predose levels. Clinical Transplantation 2010;24:E116-23. [DOI: 10.1111/j.1399-0012.2009.01183.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 62 |
Bogman K, Silkey M, Chan SP, Tomlinson B, Weber C. Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients. Eur J Clin Pharmacol 2010;66:1005-15. [DOI: 10.1007/s00228-010-0840-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 63 |
Al-khatib M, Shapiro RJ, Partovi N, Ting LSL, Ensom MHH. Pharmacokinetics of Mycophenolic Acid and its Glucuronidated Metabolites in Stable Islet Transplant Recipients. Therapeutic Drug Monitoring 2010;32:373-8. [DOI: 10.1097/ftd.0b013e3181d80c1b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 64 |
Lee JH, Yang SH, Oh JM, Lee MG. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. Journal of Pharmacy and Pharmacology 2010;62:1-23. [DOI: 10.1211/jpp.62.01.0001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 4.2] [Reference Citation Analysis]
|
| 65 |
Demir M, Gokturk HS, Ozturk NA, Serin E, Yilmaz U. Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. Am J Med Sci. 2009;338:459-464. [PMID: 19884816 DOI: 10.1097/maj.0b013e3181b5d3cf] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 66 |
Tamura M, Shiba S, Kudo N, Kawashima Y. Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus. Chirality 2010;22:92-8. [DOI: 10.1002/chir.20711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 67 |
Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737-746. [PMID: 19926034 DOI: 10.1016/s1473-3099(09)70282-8] [Cited by in Crossref: 493] [Cited by in F6Publishing: 555] [Article Influence: 35.2] [Reference Citation Analysis]
|
| 68 |
Alkharfy KM. Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. Exp Diabetes Res 2009;2009:363787. [PMID: 19859566 DOI: 10.1155/2009/363787] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 69 |
Fardel O, Le Vée M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opinion on Drug Metabolism & Toxicology 2009;5:1469-81. [DOI: 10.1517/17425250903304056] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 70 |
Fierens S, Mairesse H, Heilier J, De Burbure C, Focant J, Eppe G, De Pauw E, Bernard A. Dioxin/polychlorinated biphenyl body burden, diabetes and endometriosis: findings in a population-based study in Belgium. Biomarkers 2008;8:529-34. [DOI: 10.1080/1354750032000158420] [Cited by in Crossref: 122] [Cited by in F6Publishing: 113] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 71 |
Chadban S, Morris R, Hirsch HH, Bunnapradist S, Arns W, Budde K. Immunosuppression in renal transplantation: some aspects for the modern era. Transplantation Reviews 2008;22:241-51. [DOI: 10.1016/j.trre.2008.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 72 |
Wang CS, Yang CJ, Chen HC, Chuang SH, Chong IW, Hwang JJ, Huang MS. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009;137:203-10. [PMID: 18559125 DOI: 10.1017/S0950268808000782] [Cited by in Crossref: 77] [Cited by in F6Publishing: 88] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 73 |
Patel CG, Richman K, Yang D, Yan B, Gohh RY, Akhlaghi F. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. Ther Drug Monit 2007;29:735-42. [PMID: 18043470 DOI: 10.1097/FTD.0b013e31815d8ace] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 74 |
Cox S, Niskar AS, Narayan KM, Marcus M. Prevalence of self-reported diabetes and exposure to organochlorine pesticides among Mexican Americans: Hispanic health and nutrition examination survey, 1982-1984. Environ Health Perspect 2007;115:1747-52. [PMID: 18087594 DOI: 10.1289/ehp.10258] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 75 |
Mendonza AE, Gohh RY, Akhlaghi F. Blood and Plasma Pharmacokinetics of Ciclosporin in Diabetic Kidney Transplant Recipients: . Clinical Pharmacokinetics 2008;47:733-42. [DOI: 10.2165/00003088-200847110-00004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 76 |
Mendonza AE, Zahir H, Gohh RY, Akhlaghi F. Tacrolimus in Diabetic Kidney Transplant Recipients: Pharmacokinetics and Application of a Limited Sampling Strategy. Therapeutic Drug Monitoring 2007;29:391-8. [DOI: 10.1097/ftd.0b013e31811f319b] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 77 |
Wa C, Cerny RL, Clarke WA, Hage DS. Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta 2007;385:48-60. [PMID: 17707360 DOI: 10.1016/j.cca.2007.06.011] [Cited by in Crossref: 92] [Cited by in F6Publishing: 96] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 78 |
Pietruck F, Budde K, Salvadori M, Sollinger H, Bourbigot B, Gentil MA, Oppenheimer F. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials. Clin Transplant 2007;21:117-25. [PMID: 17302600 DOI: 10.1111/j.1399-0012.2006.00615.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 79 |
Gumustekin M, Murad N, Gidener S. Circadian variation in methotrexate toxicity in streptozotocin-induced diabetes mellitus rats. Biological Rhythm Research 2007;38:33-41. [DOI: 10.1080/09291010600832123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 80 |
Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin Dieterich H. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006;45:1125-34. [PMID: 17048976 DOI: 10.2165/00003088-200645110-00006] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 81 |
Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev 2006;19:763-87. [PMID: 17041143 DOI: 10.1128/CMR.00059-05] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 82 |
Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006;43:848-54. [PMID: 16941365 DOI: 10.1086/507543] [Cited by in Crossref: 151] [Cited by in F6Publishing: 162] [Article Influence: 8.9] [Reference Citation Analysis]
|
| 83 |
Akhlaghi F, Patel CG, Zuniga XP, Halilovic J, Preis IS, Gohh RY. Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 2006;28:95-101. [PMID: 16418701 DOI: 10.1097/01.ftd.0000189898.23931.3f] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 84 |
Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 2005;26:114-23. [PMID: 15985363 DOI: 10.1016/j.ejps.2005.05.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 85 |
Rylander L, Rignell-Hydbom A, Hagmar L. A cross-sectional study of the association between persistent organochlorine pollutants and diabetes. Environ Health 2005;4:28. [PMID: 16316471 DOI: 10.1186/1476-069X-4-28] [Cited by in Crossref: 106] [Cited by in F6Publishing: 111] [Article Influence: 5.9] [Reference Citation Analysis]
|
| 86 |
Gumustekin M, Kalkan S, Murat N, Gur O, Hocaoglu N, Gidener S. The role of circadian rhythm on the pharmacokinetic of methotrexate in streptozotocin-induced diabetes mellitus rats. Biological Rhythm Research 2005;36:277-85. [DOI: 10.1080/09291010500079692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 87 |
Leal N, Calvo R, Agrad FZ, Lukas JC, de la Fuente L, Suarez E. Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. J Pharm Pharmacol 2005;57:317-25. [PMID: 15807987 DOI: 10.1211/0022357055498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 88 |
Bae SK, Yang SH, Lee SJ, Kwon JW, Kim WB, Lee DC, Lee MG. Pharmacokinetic changes of DA-7867, a new oxazolidinone, after intravenous and oral administration to rats with short-term and long-term diabetes mellitus induced by streptozotocin. Eur J Pharm Sci 2005;25:337-45. [PMID: 15911231 DOI: 10.1016/j.ejps.2005.03.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 89 |
van Hest RM, Mathôt RA, Vulto AG, Le Meur Y, van Gelder T. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2004;26:620-5. [PMID: 15570185 DOI: 10.1097/00007691-200412000-00006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 90 |
Choi YH, Lee AK, Bae SK, Kim SO, Lee MG. Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. Biopharm Drug Dispos 2005;26:93-8. [DOI: 10.1002/bdd.436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 91 |
Kim YC, Kwon JW, Kim WB, Lee I, Lee MG. Pharmacokinetic changes of DA‐8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. Journal of Pharmaceutical Sciences 2004;93:2374-87. [DOI: 10.1002/jps.20144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 92 |
Karci A, Tasdogen A, Erkin Y, Aktaş G, Elar Z. The analgesic effect of morphine on postoperative pain in diabetic patients. Acta Anaesthesiol Scand 2004;48:619-24. [PMID: 15101859 DOI: 10.1111/j.1399-6576.2004.00387.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 93 |
Choi DH, Bae HY, Choi JS. Pharmacokinetic changes of acebutolol after oral administration in rabbits with diabetes mellitus induced by alloxan. Arch Pharm Res 2003;26:499-503. [PMID: 12877562 DOI: 10.1007/BF02976870] [Reference Citation Analysis]
|
| 94 |
Sargýn M, Uygur-Bayramiçli O, Sargýn H, Dabak R, Orbay E, Yavuzer D, Yayla A. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World J Gastroenterol 2003; 9(5): 1126-1128 [PMID: 12717872 DOI: 10.3748/wjg.v9.i5.1126] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 40] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 95 |
de la Fuente L, Lukas JC, Jauregizar N, Vázquez JA, Calvo R, Suárez E. Prediction of unbound propofol concentrations in a diabetic population. Ther Drug Monit 2002;24:689-95. [PMID: 12451283 DOI: 10.1097/00007691-200212000-00002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 96 |
Choi JS, Kim YG. Pharmacokinetic changes of diltiazem and desacetyldiltiazem after oral administration of diltiazem in rabbits with diabetes mellitus induced by alloxan. Biopharm Drug Dispos 2002;23:115-20. [PMID: 12173546 DOI: 10.1002/bdd.298] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 97 |
Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanainen P, Rautio A, Pasanen M. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol 2002;90:155-60. [PMID: 12071338 DOI: 10.1034/j.1600-0773.2002.900308.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 98 |
Preston RA, Chung M, Gaffney M, Alonso A, Baltodano NM, Epstein M. Comparative Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Patients with and without Type II Diabetes Mellitus. The Journal of Clinical Pharmacology 2001;41:1215-1224. [DOI: 10.1177/00912700122012760] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 99 |
Longnecker MP, Klebanoff MA, Brock JW, Zhou H; Collaborative Perinatal Project (CPP). Polychlorinated biphenyl serum levels in pregnant subjects with diabetes. Diabetes Care 2001;24:1099-101. [PMID: 11375377 DOI: 10.2337/diacare.24.6.1099] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 100 |
Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 2000;20:182-90. [PMID: 10678296 DOI: 10.1592/phco.20.3.182.34775] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 101 |
Al-Shabanah OA, El-Kashef HA, Badary OA, Al-Bekairi AM, Elmazar MM. Effect of streptozotocin-induced hyperglycaemia on intravenous pharmacokinetics and acute cardiotoxicity of doxorubicin in rats. Pharmacol Res 2000;41:31-7. [PMID: 10600267 DOI: 10.1006/phrs.1999.0568] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 102 |
Chung SY, Han KS, Shon SK, Chang MS, Lee MG. Pharmacokinetics of a new proton-pump inhibitor, YJA-20379-8, after intravenous and oral administration to rats with streptozotocin-induced diabetes mellitus. J Pharm Pharmacol 1999;51:929-34. [PMID: 10504032 DOI: 10.1211/0022357991773267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 103 |
Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman AJ. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J Clin Pharmacol 1997;37:1114-20. [PMID: 9506006 DOI: 10.1002/j.1552-4604.1997.tb04295.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 104 |
Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, Koup JR. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J Clin Pharmacol 1997;37:1038-47. [PMID: 9505997 DOI: 10.1002/j.1552-4604.1997.tb04285.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 105 |
Park KJ, Yoon WH, Shin WG, Lee MG. Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. J Pharm Pharmacol 1996;48:1093-7. [PMID: 8953515 DOI: 10.1111/j.2042-7158.1996.tb05906.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 106 |
Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996;30:445-62. [PMID: 8792057 DOI: 10.2165/00003088-199630060-00003] [Cited by in Crossref: 139] [Cited by in F6Publishing: 139] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 107 |
Ali SL, Blume HH, Schug BS. Sulfonylureas: Physico-chemical Properties, Analytical Methods of Determination and Bioavailability. In: Kuhlmann J, Puls W, editors. Oral Antidiabetics. Berlin: Springer Berlin Heidelberg; 1996. pp. 73-128. [DOI: 10.1007/978-3-662-09127-2_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 108 |
van Griensven JM, Jusko WJ, Lemkes HH, Kroon R, Verhorst CJ, Chiang ST, Cohen AF. Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin Pharmacol Ther 1995;58:631-40. [PMID: 8529328 DOI: 10.1016/0009-9236(95)90019-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 109 |
Olsen KM, Kearns GL, Kemp SF. Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes. J Clin Pharmacol 1995;35:739-45. [PMID: 7560255 DOI: 10.1002/j.1552-4604.1995.tb04115.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 110 |
Korrapati MR, Vestal RE, Loi CM. Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 1995;57:413-8. [PMID: 7712669 DOI: 10.1016/0009-9236(95)90210-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 111 |
Chukwuma C Sr. Type II diabetic nephropathy in perspective. J Diabetes Complications 1995;9:55-67. [PMID: 7734745 DOI: 10.1016/1056-8727(94)00004-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 112 |
Mehvar R, Reynolds J. Diabetes-induction reduction in the hepatic accumulation of 70-kDA dextran: role of hyperglycemia and hypoinsulinemia. J Pharm Sci 1994;83:1020-5. [PMID: 7525920 DOI: 10.1002/jps.2600830719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 113 |
Dressman JB, Bass P, Ritschel WA, Friend DR, Rubinstein A, Ziv E. Gastrointestinal parameters that influence oral medications. J Pharm Sci 1993;82:857-72. [PMID: 7901386 DOI: 10.1002/jps.2600820902] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 114 |
O'Byrne S, Barry MG, Collins WC, O'Connor P, Cullen MJ, Feely J. Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus. Clin Pharmacokinet 1993;24:183-6. [PMID: 8453825 DOI: 10.2165/00003088-199324020-00007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 115 |
Solomon K, Manepalli J, Ireland GA, Mahon GM. Alcoholism and prescription drug abuse in the elderly: St. Louis University grand rounds. J Am Geriatr Soc 1993;41:57-69. [PMID: 8418125 DOI: 10.1111/j.1532-5415.1993.tb05950.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 116 |
Bohney JP, Feldhoff RC. Effects of nonenzymatic glycosylation and fatty acids on tryptophan binding to human serum albumin. Biochem Pharmacol 1992;43:1829-34. [PMID: 1575775 DOI: 10.1016/0006-2952(92)90717-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 0.9] [Reference Citation Analysis]
|
